Navigation Links
Osteoarthritis: Which Treatments Work and Which Don't?
Date:2/19/2008

International society develops 25 treatment recommendations for knee and

hip osteoarthritis Findings appear in the February issue of Osteoarthritis and Cartilage

MT. LAUREL, N.J., Feb. 19 /PRNewswire/ -- A newly released set of treatment recommendations for knee and hip osteoarthritis may help millions of people worldwide who live in pain due to inconsistent treatment approaches and confusion about what therapies are most effective.

The 25 evidence-based, expert-consensus recommendations appear in the February issue of Osteoarthritis and Cartilage and can be found at http://www.oarsi.org.

These are the first evidence-based recommendations developed by a committee that was brought together two years ago by the Osteoarthritis Research Society International (OARSI). The goals were (1) to review all of the published national and regional treatment guidelines together with the more recent evidence from clinical trials and (2) to produce a single set of up-to-date, evidence-based recommendations for the worldwide treatment of knee and hip osteoarthritis.

"What the committee did was take the scientifically proven commonalities it found in the international literature, evaluate the level of scientific evidence, propose a strength of recommendation for each modality, and condense them into one comprehensive 'playbook' of what works," says OARSI President Dr. Steve Abramson, director of Rheumatology and professor of Medicine at New York University School of Medicine.

The first of OARSI's 25 evidence-based recommendations is that optimal treatment requires both nonpharmacologic and pharmacologic modalities. The remaining 24 recommendations fall into three categories -- nonpharmacologic, pharmacologic and surgical.

The effectiveness of each recommendation is associated with a level of scientific evidence available to support it. The higher the level of support (expressed as a percentage out of 100), the more evidence in the scientific literature that the treatment is effective. The following are the recommendations:

-- Nonpharmacologic -- These 11 recommendations include education and

self-management (97%); regular telephone contact (66%); referral to a

physical therapist (89%); aerobic, muscle strengthening and water-based

exercises (96%); weight reduction (96%); walking aids (90%); knee

braces (76%); footware and insoles (77%); thermal modalities (64%);

transcutaneous electrical stimulation (58%); and acupuncture (59%).

-- Pharmacologic -- These eight recommendations include acetaminophen

(92%); non-selective and selective oral nonsteroidal anti-inflammatory

drugs (NSAIDs) (93%); topical NSAIDs and capsaicin (85%);

intraarticular injections of corticosteroids (78%); intraarticular

injections of hyaluronans (64%); glucosamine and/or chondroitin

sulphate for symptom relief (63%); glucosamine sulphate, chondroitin

sulphate and/or diacerein for possible structure-modifying effects

(41%); and the use of weak opioids and narcotic analgesics for the

treatment of refractory pain (82%).

-- Surgical -- These five recommendations include total joint replacement

(96%); unicompartmental knee replacement (76%); osteotomy and joint

preserving surgical procedures (75%); joint lavage and arthroscopic

debridement in knee OA (60%); and joint fusion as a salvage procedure

when joint replacement had failed (69%).

"Our goal was to make these guidelines as simple as possible so that healthcare providers could determine which therapies would be most useful for an individual patient," says Dr. Francis Berenbaum, president elect of OARSI and a faculty member in the Department of Rheumatology at Pierre & Marie Curie University, APHP Saint-Antoine Hospital in Paris.

Nearly all of the previous guidelines were created before the recent discussion about the potential cardiovascular risks of nonsteroidal anti-inflammatory drugs (NSAIDs) took place. In recent years, there has been a decline in the use of NSAIDs to reduce pain and inflammation caused by osteoarthritis, primarily due to their potential for causing gastrointestinal side effects and the perceived cardiovascular risks associated with these drugs.

However, members of the OARSI committee found that NSAIDs are often effective pain relievers and their short-term use should be considered on a case-by-case basis and not as a long-term option.

"As a consequence of the confusion over NSAIDs, some people may not be getting the care they need for pain," says Abramson.

The OARSI recommendations make up the first truly international guidelines for the treatment of knee and hip osteoarthritis. The guideline committee was made up of experts from six countries, including 11 rheumatologists, two primary care physicians, one orthopedic surgeon, and two experts on evidence-based medicine.

Osteoarthritis is the most common type of arthritis and the major cause of chronic musculoskeletal pain and mobility limitation in elderly populations worldwide.

The Osteoarthritis Research Society International (OARSI) is a non-profit organization dedicated to promoting and encouraging fundamental and applied research, and to disseminate the results of that research in order to permit better knowledge of osteoarthritis and its treatment. For more information about OARSI visit http://www.oarsi.org.

Contact: Andrew Smith

267-884-6329

writer@comsolutionsgroup.com


'/>"/>
SOURCE Osteoarthritis Research Society International
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. FAU Receives Patent for Invention Which Induces and Restores Cardiac Muscle Function
2. Surgex(TM) Becomes the First and Only BSCG (Banned Substance Control Group) Certified Product Which is Clinically Proven Effective in Sports Recovery and Performance
3. Gilbert Hospital Continues Cutting Edge Treatments
4. New Risk Gene for Rheumatoid Arthritis and Lupus Opens Door to More Effective Treatments
5. Surgeons Develop Innovative Life-Saving Treatments to Correct Massive Bleeding in Trauma Patients
6. ASCO and ASH Release Updated Guideline on the Use of Chemotherapy-Related Anemia Treatments in Cancer Patients
7. Patient Navigators Help Minority, Low-Income Cancer Patients Get Life-Saving Treatments
8. MJFF and Merck Serono (EMD Serono in North America) Join Forces on $2-Million Initiative to Drive Treatments for PD-Related Cognitive Dysfunction and Mood Disorders
9. NanoBio Corporation Presents Preclinical and Interim Clinical Data on Topical Treatments for Herpes Labialis and Onychomycosis at AAD 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2017)... , May 5, 2017   Provista , a proven ... than 200,000 customers, today announced Jim Cunniff as ... of executive and business experience to Provista, including most recently ... in California . He assumed his new ... is a great fit for Provista," says Jody Hatcher ...
(Date:5/4/2017)... Tenn. , May 4, 2017  A ... Infection Control, Ultraviolet-C light as a ... Tru-D SmartUVC,s ability to reduce bioburden on anesthesia ... bioburden reduction on high-touch, complex medical equipment surfaces ... surgical infections. "This study further validates ...
(Date:5/4/2017)... May 4, 2017  A new tight-tolerance microextrusion ... other highly-engineered materials, is being launched by Natvar, ... been developed in recent years to service a ... surgical applications. More expensive materials such as glass ... tubing due to their ability to consistently hold ...
Breaking Medicine Technology:
(Date:5/26/2017)... ... , ... Amir Qureshi, MD is the first physician in Arkansas to implant ... The Nuvectra™ Algovita SCS System has been FDA approved as a treatment option for ... to introduce the most powerful SCS system and the only stretchable lead on the ...
(Date:5/26/2017)... ... May 26, 2017 , ... A new analysis of community health data ... are located in the Midwest. With the average cost of healthcare rising and the ... with both the quality and affordability of where they live. An annual 2017 report ...
(Date:5/26/2017)... ... May 26, 2017 , ... via seating is proud to ... task chair specifically designed for clinical areas. Genie Copper Mesh is a crossover ... Cupron® to provide customers with a game changing chair that is affordably priced,” ...
(Date:5/26/2017)... ... ... After raising nearly $30,000 on Kickstarter , about three-times its original campaign ... crowdfunding price on Indiegogo . , “Along with creating an anti-stress gadget to ... fidget toy to the market that was made of superior quality and wouldn’t break ...
(Date:5/26/2017)... (PRWEB) , ... May 26, 2017 , ... Silver Birch ... community, which is located on more than four acres of land at 5620 Sohl ... , The 103,000 square-foot building includes 125 studio and one-bedroom apartments. Each of ...
Breaking Medicine News(10 mins):